4-amino-4-oxobutyric acid N'-(1-(1-(3,5-dimethylphenyl)-2-oxo-6-trifluoromethyl-1,2-dihydroindol-3(Z)-ylidene)butyl)hydrazide | 1436931-72-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-amino-4-oxobutyric acid N'-(1-(1-(3,5-dimethylphenyl)-2-oxo-6-trifluoromethyl-1,2-dihydroindol-3(Z)-ylidene)butyl)hydrazide
• 英文别名: 4-[2-[(1Z)-1-[1-(3,5-dimethylphenyl)-2-oxo-6-(trifluoromethyl)indol-3-ylidene]butyl]hydrazinyl]-4-oxobutanamide
• CAS: 1436931-72-4
• 化学式: C₂₅H₂₇F₃N₄O₃
• 分子量: 488.51
• InChiKey: SJCUONCZMNBPEL-NMWGTECJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  35
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  105
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• [EN] METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR<br/>[FR] PROCÉDÉS ET COMPOSITIONS ASSOCIÉS AU RÉCEPTEUR DU FACTEUR DE STIMULATION DES COLONIES DE GRANULOCYTES
  申请人：LIGAND PHARM INC

  公开号：WO2013074459A1

  公开（公告）日：2013-05-23

  Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

  一些实施例包括组成物和使用或识别调节粒细胞集落刺激因子受体（GCFR）活性的化合物的方法。一些实施例包括使用化合物来治疗某些疾病，如造血或神经系统疾病。
• Methods of treatment associated with the granulocyte colony-stimulating factor receptor
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：US10420748B2

  公开（公告）日：2019-09-24

  Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.

  一些实施方案包括治疗、预防、逆转、阻止或减缓癌症进展的方法，包括向有需要的受试者施用有效量的一种或多种化疗剂，或其药学上可接受的盐，或药物组合物，其中至少一种化疗剂是细胞毒性粒细胞集落刺激因子受体（GCFR）调节剂。还公开了治疗、预防、逆转、阻止或减缓造血障碍进展的方法，包括向有需要的受试者施用治疗有效的细胞毒性量的GCFR调节剂。
• Methods and compositions associated with the granulocyte colony-stimulating factor receptor
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：US10736875B2

  公开（公告）日：2020-08-11

  Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.

  一些实施方案包括使用或鉴定调节粒细胞集落刺激因子受体（GCFR）活性的化合物的组合物和方法。一些实施方案包括使用化合物治疗某些疾病，如造血或神经系统疾病。
• METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：EP2780322B1

  公开（公告）日：2018-05-16
• METHODS OF TREATMENT ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR
  申请人：LIGAND PHARMACEUTICALS INCORPORATED

  公开号：US20160022638A1

  公开（公告）日：2016-01-28

  Some embodiments include methods for treating, preventing, reversing, halting, or slowing the progression of cancer, comprising administering to a subject in need thereof an effective amount of one or more chemotherapeutic agents, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, wherein at least one of the chemotherapeutic agents is a cytotoxic granulocyte colony-stimulating factor receptor (GCFR) modulator. Methods are also disclosed for treating, preventing, reversing, halting, or slowing the progression of a hematopoietic disorder, comprising administered a therapeutically effective cytotoxic amount of a GCFR modulator to a subject in need thereof.